Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$33.38+0.40 (+1.21%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%
Castle Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Castle Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$28.04M. For fiscal 2025 it was -$42.81M, down 593.8% from the year before. The highest annual figure on record is $8.67M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.81M | -593.8% |
| FY2024 | Dec 31, 2024 | $8.67M | – |
| FY2023 | Dec 31, 2023 | -$67.98M | – |
| FY2022 | Dec 31, 2022 | -$72.86M | – |
| FY2021 | Dec 31, 2021 | -$40.08M | – |
| FY2020 | Dec 31, 2020 | -$6.54M | -189.3% |
| FY2019 | Dec 31, 2019 | $7.33M | – |
| FY2018 | Dec 31, 2018 | -$3.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.73M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.83M | -194.5% |
| Q3 FY2025 | Sep 30, 2025 | -$6.80M | -234.0% |
| Q2 FY2025 | Jun 30, 2025 | -$4.25M | -184.8% |
| Q1 FY2025 | Mar 31, 2025 | -$27.93M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.05M | – |
| Q3 FY2024 | Sep 30, 2024 | $5.08M | – |
| Q2 FY2024 | Jun 30, 2024 | $5.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.81M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.81M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.28M | -513.5% |
| Q4 FY2020 | Dec 31, 2020 | -$3.03M | -216.0% |
| Q3 FY2020 | Sep 30, 2020 | -$3.90M | -188.1% |
| Q2 FY2020 | Jun 30, 2020 | -$645.00K | -206.1% |
| Q1 FY2020 | Mar 31, 2020 | $1.04M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.61M | -45.2% |
| Q3 FY2019 | Sep 30, 2019 | $4.43M | – |
| Q2 FY2019 | Jun 30, 2019 | $608.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$322.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $4.77M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.85M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.67M | – |
See a number that looks wrong?